Grail (NASDAQ:GRAL - Get Free Report) had its price target boosted by Morgan Stanley from $16.00 to $20.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has an "equal weight" rating on the stock. Morgan Stanley's price objective indicates a potential downside of 33.97% from the stock's current price.
Grail Stock Up 8.9 %
Shares of Grail stock traded up $2.48 during trading on Tuesday, reaching $30.29. The company's stock had a trading volume of 1,739,247 shares, compared to its average volume of 1,224,238. Grail has a 12-month low of $12.33 and a 12-month high of $63.99. The business has a 50 day moving average price of $32.87 and a 200-day moving average price of $21.85.
Grail (NASDAQ:GRAL - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share for the quarter, beating analysts' consensus estimates of ($4.41) by $2.55. The business had revenue of $38.25 million during the quarter, compared to analysts' expectations of $35.33 million. On average, sell-side analysts predict that Grail will post -15.15 EPS for the current fiscal year.
Insider Activity at Grail
In other Grail news, CEO Robert P. Ragusa sold 7,625 shares of the business's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $31.21, for a total transaction of $237,976.25. Following the sale, the chief executive officer now directly owns 828,662 shares in the company, valued at approximately $25,862,541.02. The trade was a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President Joshua J. Ofman sold 2,109 shares of the business's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $65,800.80. Following the sale, the president now owns 559,673 shares in the company, valued at approximately $17,461,797.60. The trade was a 0.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,550 shares of company stock worth $360,436 over the last three months.
Institutional Trading of Grail
Institutional investors have recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in Grail during the fourth quarter worth $26,000. Lindbrook Capital LLC purchased a new stake in shares of Grail in the fourth quarter valued at $28,000. State of Tennessee Department of Treasury purchased a new stake in shares of Grail in the fourth quarter valued at $28,000. Sterling Capital Management LLC purchased a new stake in shares of Grail in the fourth quarter valued at $29,000. Finally, Wellington Shields Capital Management LLC purchased a new stake in shares of Grail in the fourth quarter valued at $33,000.
Grail Company Profile
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Featured Articles
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
